Eyepoint Pharmaceuticals Inc (EYPT) Director Purchases $29,750.00 in Stock

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) Director Douglas Evan Godshall purchased 17,000 shares of the firm’s stock in a transaction that occurred on Friday, March 29th. The shares were bought at an average cost of $1.75 per share, with a total value of $29,750.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

NASDAQ:EYPT traded down $0.01 during mid-day trading on Wednesday, reaching $1.70. The company’s stock had a trading volume of 355,307 shares, compared to its average volume of 409,465. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.37. Eyepoint Pharmaceuticals Inc has a twelve month low of $1.24 and a twelve month high of $3.94. The firm has a market cap of $154.50 million, a price-to-earnings ratio of -2.93 and a beta of 1.95.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Eyepoint Pharmaceuticals had a negative return on equity of 192.19% and a negative net margin of 1,884.18%. The firm had revenue of $2.44 million for the quarter, compared to analyst estimates of $0.66 million. As a group, research analysts forecast that Eyepoint Pharmaceuticals Inc will post -0.32 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on EYPT shares. Zacks Investment Research downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 15th. ValuEngine cut Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. Finally, HC Wainwright set a $5.00 price objective on Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, January 4th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp acquired a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at about $218,000. Vanguard Group Inc lifted its stake in shares of Eyepoint Pharmaceuticals by 2.7% in the 3rd quarter. Vanguard Group Inc now owns 1,798,708 shares of the company’s stock valued at $6,422,000 after purchasing an additional 47,361 shares in the last quarter. Private Advisor Group LLC acquired a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at about $134,000. Vanguard Group Inc. lifted its stake in shares of Eyepoint Pharmaceuticals by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,798,708 shares of the company’s stock valued at $6,422,000 after purchasing an additional 47,361 shares in the last quarter. Finally, B. Riley Wealth Management Inc. acquired a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at about $164,000. 57.79% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Eyepoint Pharmaceuticals Inc (EYPT) Director Purchases $29,750.00 in Stock” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/24/eyepoint-pharmaceuticals-inc-eypt-director-douglas-evan-godshall-acquires-17000-shares.html.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Featured Story: Fundamental Analysis – How It Helps Investors

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.